Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM

References

• Pearson-Stuttard J, Bennett J, Cheng YJ, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9(3):165–173. doi: 10.1016/S2213-8587(20)30431-9
   PubMed Web of Science ®Google Scholar
• Wang P, Kang D, Cao W, et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28(2):109–122. doi: 10.1002/dmrr.1291
   PubMed Web of Science ®Google Scholar
• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi: 10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–2195. doi: 10.1002/hep.26986
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease Study 2015. JAMA Oncol. 2017;3(12):1683–1691. doi: 10.1001/jamaoncol.2017.3055
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM. EASL Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi: 10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147:317–330. doi: 10.1002/ijc.32723
   PubMed Web of Science ®Google Scholar
• Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. 2022;20:283–92 e10. doi: 10.1016/j.cgh.2021.05.002
   PubMed Web of Science ®Google Scholar
• Wild SH, Morling JR, McAllister DA, et al. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. J Hepatol. 2016;64(6):1358–1364. doi: 10.1016/j.jhep.2016.01.014
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Muraca E, Perra S, et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8(1):e000904. doi: 10.1136/bmjdrc-2019-000904
   PubMed Web of Science ®Google Scholar
• Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 2021;44(2):399–406. doi: 10.2337/dc20-1997
   PubMed Web of Science ®Google Scholar
• Wild SH, Walker JJ, Morling JR, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41(2):341–347. doi: 10.2337/dc17-1590
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi: 10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang Y, Graham S, et al. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 2020;73(2):263–276. doi: 10.1016/j.jhep.2020.03.006
   PubMed Web of Science ®Google Scholar
• Byrne CD. Banting memorial lecture 2022: ‘type 2 diabetes and nonalcoholic fatty liver disease: partners in crime’. Diabet Med. 2022;39(10):e14912. doi: 10.1111/dme.14912
   PubMed Web of Science ®Google Scholar
• Kwo PY, Cohen SM, Lim JK. ACG Clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi: 10.1038/ajg.2016.517
   PubMed Web of Science ®Google Scholar
• Panteghini M, Adeli K, Ceriotti F, et al. American liver guidelines and cutoffs for “normal” ALT: a potential for overdiagnosis. Clin Chem. 2017;63(7):1196–1198. doi: 10.1373/clinchem.2017.274977
   PubMed Web of Science ®Google Scholar
• Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:61–71 e15. doi: 10.1016/j.cgh.2020.04.067
   PubMed Web of Science ®Google Scholar
• Buckley BS, Harreiter J, Damm P, et al. Gestational diabetes mellitus in Europe: prevalence, current screening practice and barriers to screening. A review. Diabet Med. 2012;29(7):844–854. doi: 10.1111/j.1464-5491.2011.03541.x
   PubMed Web of Science ®Google Scholar
• Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90:4004–4010. doi: 10.1210/jc.2004-1713
   PubMed Web of Science ®Google Scholar
• Forbes S, Taylor-Robinson SD, Patel N, et al. Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes. Diabetologia. 2011;54(3):641–647. doi: 10.1007/s00125-010-2009-0
   PubMed Web of Science ®Google Scholar
• Cho Y, Chang Y, Ryu S, et al. History of gestational diabetes and incident nonalcoholic fatty liver disease: The Kangbuk Samsung Health Study. Am J Gastroenterol. 2023; Publish Ahead of Print. doi: 10.14309/ajg.0000000000002250.
   Google Scholar
• Cho Y, Chang Y, Ryu S, et al. Synergistic effect of non-alcoholic fatty liver disease and history of gestational diabetes to increase risk of type 2 diabetes. Eur J Epidemiol. 2023;38(8):901–911. doi: 10.1007/s10654-023-01016-1
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–1725. doi: 10.1053/gast.2002.36572
   PubMedGoogle Scholar
• Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology. 2005;41(2):372–379. doi: 10.1002/hep.20554
   PubMed Web of Science ®Google Scholar
• Tan DJH, Ng CH, Lin SY, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521–530. doi: 10.1016/S1470-2045(22)00078-X
   PubMed Web of Science ®Google Scholar
• Singal AG, Zhang E, Narasimman M, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–139. doi: 10.1016/j.jhep.2022.01.023
   PubMed Web of Science ®Google Scholar
• Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–1501. doi: 10.1002/hep.29302
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Felix S, Jeffers T, et al. Performance of the Enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease. JAMA Netw Open. 2021;4(9):e2123923. doi: 10.1001/jamanetworkopen.2021.23923
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17:156–63 e2. doi: 10.1016/j.cgh.2018.04.043
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67(1):134–144. doi: 10.1002/hep.29489
   PubMed Web of Science ®Google Scholar
• Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(6):1717–1730. doi: 10.1053/j.gastro.2019.01.042
   PubMed Web of Science ®Google Scholar
• Hur KY, Moon MK, Park JS, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021;45:461–481. doi: 10.4093/dmj.2021.0156
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care. 2023;46:S49–S67. doi: 10.2337/dc23-S004
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. London: NICE; 2015. ( NICE guideline [NG28]). https://www.nice.org.uk/guidance/ng28
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Non-alcoholic fatty liver disease (NAFLD): assessment and management. London: NICE; 2016. ( NICE guideline [NG49]). https://www.nice.org.uk/guidance/ng49
   Google Scholar
• European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016; 59:1121–1140. doi: 10.1007/s00125-016-3902-y
   PubMed Web of Science ®Google Scholar
• Harrison P, Hogan BJ, Floros L, et al. Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance. BMJ. 2016;354:i2850. doi: 10.1136/bmj.i2850
   PubMedGoogle Scholar
• Glen J, Floros L, Day C, et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance. BMJ. 2016;354:i4428. doi: 10.1136/bmj.i4428
   PubMedGoogle Scholar
• Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–378. doi: 10.1016/j.jhep.2019.03.033
   PubMed Web of Science ®Google Scholar
• Reinson T. Performance of the Enhanced liver fibrosis score, comparison with vibration-controlled transient elastography data, and development of a simple algorithm to predict significant liver fibrosis in a community-based liver service: a retrospective evaluation. J Clin Transl Hepatol. 2023;11(4):800–808. doi: 10.14218/JCTH.2022.00335
   PubMedGoogle Scholar
• Mansour D, Grapes A, Herscovitz M, et al. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep. 2021;3(4):100293. doi: 10.1016/j.jhepr.2021.100293
   PubMedGoogle Scholar
• Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913. doi: 10.1016/S2468-1253(21)00308-3
   PubMed Web of Science ®Google Scholar
• Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. Gut. 2022. doi:10.1136/gutjnl-2020-323082.
   Google Scholar
• Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156–162. doi: 10.1136/gutjnl-2020-323082
   PubMed Web of Science ®Google Scholar
• Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2023;8(2):179–191. doi: 10.1016/S2468-1253(22)00338-7
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17(9):1877–85.e5. doi: 10.1016/j.cgh.2018.12.031
   PubMed Web of Science ®Google Scholar
• Jennison E, Byrne CD. Recent advances in NAFLD: current areas of contention. Faculty Reviews. 2023;12:10. doi: 10.12703/r/12-10
   PubMedGoogle Scholar
• Reinson T, Buchanan RM, Byrne CD. Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future. Clin Mol Hepatol. 2023;29(Suppl):SS157–sS170. doi: 10.3350/cmh.2022.0348
   Google Scholar